News | October 23, 2022
Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Revenue from operations up 26% to Rs. 768 crores
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
